Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Apoxis
Swiss company wins award for cancer drug development
June 15th, 2005
The hope of finding a new drug that could revolutionize cancer treatment must have had a broad appeal to the jury of the Swiss Technology Award. This became evident on February 19, 2004, when Apoxis was pronounced the winner of the Swiss Technology Award in Bern. The prize was given for Apoxis proprietary MegaLigand technology, an innovative technology, which generates recombinant proteins that kill cancer cells by apoptosis (programmed cell death). Of the 58 companies bidding for the prize, 18 were short-listed, from which four finalists were selected. In November 2003, Apoxis received the encouraging word that the company was...
Source: Physician Law Weekly (2005-06-15)
|
